- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Merus Announces $27 Million Bought Deal
Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) has entered into an agreement with a syndicate of underwriters co-led by Canaccord Genuity Corp. and Clarus Securities Inc. to purchase, on a bought deal private placement basis, 14,250,000 subscription receipts of the company at a price of $1.90 per Subscription Receipt, for aggregate gross proceeds of $27,075,000.
Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) has entered into an agreement with a syndicate of underwriters co-led by Canaccord Genuity Corp. and Clarus Securities Inc. to purchase, on a bought deal private placement basis, 14,250,000 subscription receipts of the company at a price of $1.90 per Subscription Receipt, for aggregate gross proceeds of $27,075,000.
According to the company news:
The 2015 annual report includes several sections featuring ARM member company perspectives, highlighting important focus areas for the sector:
- The partnering and dealmaking environment, with commentary from Cellular Dynamics International (a FUJIFILM company), Novartis and Voyager Therapeutics, Inc.
- Europe’s regenerative medicine and advanced therapy sector, with commentary from Cellectis, Celyad and Bone Therapeutics.
- CAR-T and adoptive T-cell therapies, with commentary from Juno Therapeutics and Novartis.
- Gene editing technologies, with commentary from Cellectis, Precision BioSciences and Sangamo BioSciences.
Morrie Ruffin, ARM’s managing director commented:
This past year was a watershed in terms of the amount of money raised by gene and cell therapy companies, as well as the vote of confidence in the sector from large pharma and large-cap biotech companies, visible in the record number of investments and high-value corporate partnerships. We recognize, however, that the financing environment has changed significantly since Q3 2015 and the greatest need now is to continue to show steady, meaningful clinical progress in areas of significant unmet medical need.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.